Current Report Filing (8-k)
March 17 2017 - 10:45AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
March 15, 2017
Freedom Leaf Inc.
(Exact name of registrant as specified in its
charter)
Nevada
(State or Other Jurisdiction of Incorporation)
000-55687
|
46-2093679
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
3571 E. Sunset Road, Suite 420
Las Vegas, NV
|
89120
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(877) 442-0411
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
☐
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
|
ITEM 1.01
|
ENTRY INTO A DEFINITIVE MATERIAL AGREEMENT
|
On March 15, 2017, Freedom Leaf Inc. (the “Company”)
entered into an Exclusive Distribution Agreement (the “Distribution Agreement”) with NuAxon Bioscience, Inc. (“NuAxon”)
to sell NuAxon’s CO2 extraction equipment pursuant to which the Company would be paid increasing commissions depending on
gross sales of the equipment.
On March 16, 2017, the Company issued a purchase
order (the “Purchase Order”) to NuAxon to purchase extraction equipment for one of the Company’s customers.
The foregoing descriptions of the Distribution
Agreement and the Purchase Order are qualified in their entirety by the full text of such agreements, which are filed as Exhibits
10.4 and 10.5 to, and incorporated by reference in, this report.
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
The exhibits listed in the following Exhibit
Index are filed as part of this report:
10.4 Distribution Agreement
with NuAxon Bioscience, Inc.
10.5 Purchase Order with
NuAxon Bioscience, Inc.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 17, 2017
|
FREEDOM LEAF, INC.
|
|
|
|
By:
/s/ Clifford J. Perry
|
|
Clifford J. Perry
|
|
Chief Executive Officer & Director
|